In a remarkable display of robust growth and steadfast commitment to innovation and sustainability, Chiesi Group, the Italy-based international biopharmaceutical conglomerate, has announced its revenue for the year 2023, which has impressively surpassed the €3 billion mark. This significant financial achievement denotes a 10% increase from the previous year, with an even more pronounced growth rate of 12% at constant exchange rates.

Chiesi Group, headquartered in Parma, Italy, has long been recognized for its pioneering work in the pharmaceutical industry, particularly in areas of respiratory health, rare diseases, and specialty care. With 31 global affiliates and a workforce exceeding 7,000, the company has continually focused on enhancing patient care through innovative therapeutic solutions.

2023 turned out to be an exemplary year for Chiesi, evidencing a strong performance across all its business segments, particularly the Rare Diseases unit which saw an astronomical growth of 65% at constant exchange rates. This unit alone amassed over €540 million in sales, thanks significantly to strategic expansions like the acquisition of Amryt Pharma Plc, thereby broadening the spectrum of rare diseases addressed by Chiesi.

Further underlining its focus on innovation, Chiesi dedicated nearly a quarter of its total sales revenue to research and development (R&D). This substantial investment fuels both the internal development pipeline and various external collaborations aimed at bringing novel treatments to the market. Such commitment is evident with the FDA’s approval of the first pharmacological therapy for Alpha-Mannosidosis in early 2023, among other approvals across the globe for treatments targeting severe and rare medical conditions.

Chiesi’s AIR business area, which deals with respiratory diseases and accounts for over half of the company’s total revenue, also saw notable advancements. The introduction of a fixed triple formulation for asthma and COPD in China marks a significant step in enhancing access to critical care in respiratory health within the region. Additionally, the company’s endeavors in partnership with firms like Affibody AB and Haisco Pharmaceutical to expand and improve its respiratory health portfolio have poised Chiesi as a leader in this crucial therapeutic area.

On the sustainability front, Chiesi continues to excel as a paradigm of corporate responsibility. The company’s sterling commitment to achieving Net-Zero greenhouse gas emissions by 2035 is accompanied by noteworthy recognitions such as an A- rating from the Carbon Disclosure Project and a Platinum medal from Ecovadis.

The company’s conscientious approach extends to its corporate culture as well. For the third consecutive time, Chiesi has earned the certification as a Great Place to Work™, reflecting its dedication to fostering an inclusive and supportive work environment across its expanding global presence.

Looking ahead to 2024, Chiesi intends to maintain its trajectory of growth while continuing to champion sustainable, patient-centric innovations. The inauguration of its new Biotech Center of Excellence in Parma signifies a bold step towards enhanced capabilities in biologic drug development and production. Additionally, the company plans to refine its greenhouse gas emissions reduction targets in line with the latest science-based standards.

Chiesi’s impressive performance in 2023 not only exemplifies its role as a leader in pharmaceutical innovation but also highlights its commitment as a socially responsible entity dedicated to advancing global health and sustainability. With its strategic initiatives, Chiesi Group is set to continue making significant impacts on healthcare and the environment, reinforcing its position at the forefront of the pharmaceutical industry.